Cargando…
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
Purpose: Immune checkpoint inhibitors are effective therapies for advanced hepatocellular carcinoma (HCC); however, comparisons of the clinical efficacy and safety profile for these drugs are still scarce. Thus, the aims of this study were to investigate the differences in efficacy and safety betwee...
Autores principales: | Kuo, Hsin-Yu, Han, Meng-Zhi, Liao, Chih-Hsiang, Lin, Yih-Jyh, Wang, Chung-Teng, Chen, Shang-Hung, Chang, Ting-Tsung, Chen, Po-Jun, Lin, Sheng-Hsiang, Chen, Chiung-Yu, Chuang, Chiao-Hsiung, Wu, I-Chin, Wu, Juei-Seng, Hong, Tzu-Chun, Hsieh, Ming-Tsung, Lee, Yang-Cheng, Wu, Hung-Tsung, Tsai, Hong-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697961/ https://www.ncbi.nlm.nih.gov/pubmed/36365082 http://dx.doi.org/10.3390/pharmaceutics14112263 |
Ejemplares similares
-
Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023) -
Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan
por: Wu, Juei-Seng, et al.
Publicado: (2023) -
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022) -
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
por: Tsai, Hong-Ming, et al.
Publicado: (2021) -
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)